Therapeutic Asset Ratings

Thiotepa

Atezolizumab

allogeneic natural killer (NK) cells isolated from peripheral blood leukapheresis of individual donors. The cells are co-cultured in media containing interleukin 15 (IL-15) and nicotinamide (NAM, niacinamide) with expansion enhanced by the presence of feeder cells. The final cell population consists of 97-99% CD3-CD56+ NK cells, with >10% expressing CD16 (also known as Fc?RIII) and CD62L (also known as L-selectin) and with capacity to degranulate (surface expression of CD107? [Lysosome-associated membrane glycoprotein 1]; >10%), and to kill target cells (>10%) in co-culture assays against human cancer cell lines.

Tisagenlecleucel

Cart-19 Cells

Moderna Bivalent Mrna Vaccine

pf-05280586

Pfizer Bivalent Covid-19 Vaccine

Rituximab arrx

RITUXIMAB BIOSIMILAR (CELLTRION)

Azacitidine

DARATUMUMAB

Durvalumab

Jcar017 (Lisocabtagene Maraleucel)

Multi-Peptide Cmv-Modified Vaccinia Ankara Vaccine

Pneumococcal Polyvalent Vaccine

Polatuzumab Vedotin

Tocilizumab

Zilovertamab Vedotin

Allopurinol

Ruxolitinib Phosphate

Umbralisib

MODERNA COVID-19 VACCINE RNA

Mosunetuzumab

ca-4948